Hospital
Gaston Memorial Hospital, Incorporated
Gaston Memorial Hospital, Incorporated was paid $49.28M by Medicaid between Jan 2018 and Dec 2024, across 124 billing codes. Its largest line is 99285, emergency room visit (most serious) — 34% of everything it billed.
33Billing provider infoGASTON MEMORIAL HOSPITAL, INCORPORATED
GASTONIA, NC 28054
GASTONIA, NC 28054
33aNPI1013918960assigned 08/02/2005
33bProvider typeGeneral Acute Care Hospital
28Total paid$49.28M
24GClaims904,290
24DCodes billed124
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other General Acute Care Hospital providers in North Carolina
Rank by total paid#9 of 92
Median peer was paid$11.47M
This provider vs. median4.3×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 101,791 | $4.90M | |
| 2019 | 94,973 | $4.88M | |
| 2020 | 78,888 | $2.99M | |
| 2021 | 102,436 | $6.50M | |
| 2022 | 156,175 | $9.02M | |
| 2023 | 179,251 | $9.68M | |
| 2024incomplete | 190,776 | $11.32M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 34% | 64,998 | 59,322 | $16.60M |
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 24% | 88,223 | 81,943 | $11.90M |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 18% | 38,800 | 35,642 | $8.75M |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | 2.6% | 23,205 | 20,556 | $1.29M |
| 71045 | Radiologic examination, chest; single view | 2.3% | 34,441 | 31,295 | $1.12M |
| 41899 | Unlisted procedure, dentoalveolar structures | 2.1% | 953 | 867 | $1.02M |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | 1.5% | 26,208 | 23,864 | $743K |
| 80053 | Comprehensive metabolic panel | 1.4% | 73,427 | 65,900 | $711K |
| 87400 | 1.3% | 46,796 | 21,602 | $656K | |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | 1.2% | 81,201 | 72,912 | $605K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | 1.2% | 25,443 | 22,612 | $585K |
| 96361 | Intravenous infusion, hydration; each additional hour | <1% | 20,125 | 12,153 | $426K |
112 more codes
| 59025 | Fetal non-stress test | <1% | 7,186 | $382K |
| J3490 | Unclassified drugs | <1% | 59,418 | $363K |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 14,299 | $360K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 4,066 | $285K |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | <1% | 367 | $254K |
| 87430 | <1% | 15,055 | $240K | |
| 11042 | Debridement, subcutaneous tissue (includes epidermis, dermis, and subcutaneous tissue); first 20 sq cm | <1% | 3,252 | $220K |
| 99213 | Doctor's office visit, returning patient (routine) | <1% | 8,997 | $211K |
| 84703 | <1% | 16,735 | $199K | |
| 81001 | <1% | 55,022 | $185K | |
| 87070 | <1% | 13,295 | $160K | |
| 96413 | Chemotherapy administration, intravenous infusion; up to 1 hour, single or initial substance | <1% | 1,247 | $126K |
| 84484 | <1% | 14,804 | $118K | |
| J7120 | Ringers lactate infusion, up to 1000 cc | <1% | 7,792 | $116K |
| 70450 | Computed tomography, head or brain; without contrast material | <1% | 614 | $115K |
| 87426 | Infectious agent antigen detection, SARS-CoV-2 (COVID-19) | <1% | 2,496 | $112K |
| 95810 | Polysomnography; sleep staging with 4 or more additional parameters | <1% | 259 | $92K |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 5,400 | $87K |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | <1% | 2,566 | $85K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 4,385 | $81K |
| 83690 | <1% | 10,768 | $80K | |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 7,646 | $72K |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 2,606 | $68K |
| 71046 | Radiologic examination, chest; 2 views | <1% | 2,025 | $65K |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 7,568 | $64K |
| J7050 | Infusion, normal saline solution, 250 cc | <1% | 4,465 | $55K |
| 95811 | <1% | 115 | $48K | |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 655 | $39K |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 5,585 | $36K |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 2,373 | $36K |
| 83605 | <1% | 3,248 | $35K | |
| 99214 | Doctor's office visit, returning patient (more involved) | <1% | 926 | $31K |
| 81025 | <1% | 3,042 | $29K | |
| 87420 | <1% | 1,504 | $28K | |
| 87536 | <1% | 467 | $27K | |
| A9270 | Non-covered item or service | <1% | 65,384 | $26K |
| 87077 | <1% | 2,497 | $25K | |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 1,264 | $23K |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 295 | $18K |
| 0002A | <1% | 336 | $15K | |
| J2704 | Injection, propofol, 10 mg | <1% | 1,602 | $15K |
| 96367 | <1% | 175 | $15K | |
| 0001A | <1% | 373 | $14K | |
| 36415 | Collection of venous blood by venipuncture | <1% | 5,725 | $14K |
| G0378 | Hospital observation service, per hour | <1% | 67 | $13K |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 439 | $12K |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 439 | $12K |
| 11045 | <1% | 30 | $11K | |
| 86361 | <1% | 316 | $11K | |
| 83735 | <1% | 1,576 | $10K | |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | <1% | 14 | $9K |
| 80061 | Lipid panel | <1% | 625 | $9K |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 1,081 | $9K |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 984 | $8K |
| 72114 | <1% | 161 | $8K | |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 701 | $8K |
| 77336 | <1% | 65 | $6K | |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | <1% | 80 | $6K |
| 85027 | <1% | 747 | $5K | |
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | <1% | 25 | $5K |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 163 | $4K |
| 72052 | <1% | 38 | $3K | |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | <1% | 169 | $3K |
| 72110 | <1% | 114 | $3K | |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | <1% | 199 | $3K |
| 74018 | <1% | 89 | $3K | |
| 83880 | <1% | 97 | $3K | |
| 85730 | <1% | 573 | $3K | |
| 80076 | <1% | 335 | $3K | |
| J0690 | Injection, cefazolin sodium, 500 mg | <1% | 49 | $2K |
| 85610 | <1% | 643 | $2K | |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | <1% | 73 | $2K |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 207 | $2K |
| 86780 | <1% | 108 | $2K | |
| 94726 | <1% | 15 | $2K | |
| 76001 | <1% | 13 | $1K | |
| 87631 | <1% | 15 | $1K | |
| J1642 | Injection, heparin sodium, (heparin lock flush), per 10 units | <1% | 764 | $1K |
| 87641 | <1% | 77 | $1K | |
| 86850 | <1% | 117 | $1K | |
| 82565 | <1% | 209 | $1K | |
| 94729 | <1% | 13 | $756.21 | |
| J2001 | Injection, lidocaine hcl for intravenous infusion, 10 mg | <1% | 94 | $580.69 |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 56 | $467.68 |
| 87486 | <1% | 15 | $448.23 | |
| 87581 | <1% | 15 | $448.23 | |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 52 | $400.41 |
| 72020 | <1% | 13 | $400.30 | |
| 84439 | <1% | 52 | $396.07 | |
| J1040 | Injection, methylprednisolone acetate, 80 mg | <1% | 92 | $324.80 |
| 82805 | <1% | 14 | $318.24 | |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 14 | $290.48 |
| 84702 | <1% | 25 | $289.44 | |
| 82533 | <1% | 13 | $243.84 | |
| 87040 | <1% | 84 | $239.16 | |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | <1% | 28 | $237.91 |
| 86901 | <1% | 100 | $231.22 | |
| 86900 | <1% | 100 | $230.02 | |
| 86762 | <1% | 13 | $209.76 | |
| 86787 | <1% | 13 | $188.00 | |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 44 | $187.19 |
| 87210 | <1% | 47 | $186.05 | |
| 86200 | <1% | 13 | $177.43 | |
| J0330 | Injection, succinylcholine chloride, up to 20 mg | <1% | 13 | $174.22 |
| 87340 | <1% | 13 | $135.79 | |
| J0131 | Injection, acetaminophen, not otherwise specified,10 mg | <1% | 34 | $134.77 |
| 82800 | <1% | 15 | $83.24 | |
| 86592 | <1% | 14 | $58.41 | |
| J8540 | Dexamethasone, oral, 0.25 mg | <1% | 15 | $27.84 |
| J7512 | Prednisone, immediate release or delayed release, oral, 1 mg | <1% | 17 | $18.74 |
| J7620 | Albuterol, up to 2.5 mg and ipratropium bromide, up to 0.5 mg, fda-approved final product, non-compounded, administered through dme | <1% | 110 | $3.32 |
| J7999 | Compounded drug, not otherwise classified | 0% | 13 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialO'CONNOR, DAVID (VICE PRESIDENT / CFO)
| Provider | Location | Paid |
|---|---|---|
| Caromont Health Services, INC. | Gastonia, NC | $758K |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.